Trial · NCT06681220
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
NCT06681220, Phase 1, Phase 2, Recruiting, VA Office of Research and Development
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC. Trials, record NCT06681220. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06681220
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- NCT number
- NCT06681220
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 166 participants, estimated
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- Stenoparib/Temozolomide, Lurbinectedin, Stenoparib/Temozolomide
- First posted
- 2024-11-08
- Last updated
- 2026-03-11
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Through study completion up to 2 years. | According to response evaluation criteria in solid tumors RECIST 1.1(imaging criteria or progression or patient death). |
| Primary | Recommended Phase 2 dose | Through end of cycle 1 (21 days) | Defined as the recommended dose of Stenoparib for phase 2 |
| Secondary | Disease control rate (DCR) | Through study completion up to 2 years. | Defined as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) per RECIST 1.1. |
| Secondary | Overall Survival (OS) | Through study completion up to 2 years. | Will be measured from Day 1 of treatment until death from any cause. |
| Secondary | Overall response rate (ORR) | Through study completion up to 2 years. | Defined as complete response (CR) + partial response (PR) per RECIST 1.1 criteria. |
| Secondary | Treatment Toxicities | Through study completion up to 2 years. | As defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. |
| Secondary | Progression Free Survival (PFS) | Through study completion up to 2 years. | Compare PFS between biomarker positive and biomarker negative patient receiving Lurbinectedin. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06681220
GET https://conductscience.org/api/trials/v1/NCT06681220/registered